Christian Schröter

KBC Asset Management NV (KBC AM) is the wholly-owned asset management subsidiary of KBC Bank NV, itself a subsidiary of KBC Group SA/NV (XB: KBC; ADR: KBCSY) in Belgium. The firm was founded in 2000 and is previously a division of KBC Bank. Headquartered in Brussels, KBC AM provides asset management services to private individuals, corporate clients and institutions. They also manage a range of mutual funds across various asset classes, markets and strategies.

Participatiemaatschappij Vlaanderen NV (PMV) is a private equity/venture capital firm, a subsidiary of Region of Flanders founded in 1995. Participatiemaatschappij Vlaanderen NV is headquartered in Brussels, Belgium.

Evotec International GmbH develops and provides drugs for the treatment of CNS disorders. It focuses on Alzheimer's disease and other neurological disorders. The company was founded in 1999 and is headquartered in Hamburg, Germany.

Gimv (Private Equity) is a Private Equity firm, a subsidiary of Gimv NV (XB: GIMB) founded in 1980. Gimv (Private Equity) is headquartered in Antwerp, Belgium.

EMBL Ventures GmbH (EMBL Ventures) is a venture investment arm of EMBL which was founded in 2001 by Drs. Stefan Herr, Christoph Antz and Jan Adams to provide start-up companies exploiting EMBL research and intellectual property with equity and expertise to build up and expand their business. Headquartered in Heidelberg, EMBL Ventures manages funds on behalf of institutional and private investors, forming a triad with EMBL (European Molecular Biology Laboratory) and EMBLEM (EMBL Enterprise Management Technology Transfer GmbH) to provide exclusive access to unique technology commercialization opportunities from the EMBL. In addition, their investment activities complement and exploit synergies with EMBL and EMBLEM, providing financial and strategic investors with access to an attractive private equity market and an international scientific and research community, respectively.

Novartis Institutes for Biomedical Research, Inc. conducts biomedical researches. It focuses in the areas of oncology, ophthalmology, diabetes, musculoskeletal disorders, neuroscience, and cardiovascular conditions, other focus areas include discovery chemistry, biologics, pathway biology, and translational medicine. The company was founded on September 10, 2002 and is headquartered in Cambridge, MA.

Keystone Symposia operates as a catalyst for the advancement of biomedical and life sciences by connecting scientists within and across disciplines at conferences and workshops. The company was founded by C. Fred Fox in 1972 and is headquartered in Silverthorne, CO.

Capricorn Health-Tech Fund NV invests in companies located in Western Europe. It targets companies operating in the fields of human health-technology. It provides financing for seed stage, early stage and growth stage in equity and debt with an investment size between €0.5 million - €6 million. It acquires mostly minority stakes but also majority stakes.

Q-Biologicals NV operates as a bio pharma contract development and manufacturing organization. It provides process development and bio manufacturing services to customers in the biopharmaceutical industry. The company was founded in 2011 and is headquartered in Ghent, Belgium.

Eternygen GmbH engages in the research and development of drugs. It develops new drugs for dietary-related metabolic diseases which include obesity, diabetes mellitus and fatty liver. The company was founded by Marco J. Janezic in June 2012 and is headquartered in Berlin, Germany.

Epidarex Capital Partners LLC (Epidarex Capital) is a venture capital firm founded in 2010 by Kyparissia Sirinakisvin. The firm is headquartered in Bethesda, Maryland.

Allecra Therapeutics GmbH focuses on the development of novel treatments to combat multi drug-resistant bacterial infections. The firm serves the bio and pharmaceutical industry. The company was founded by Nicholas Benedict and Stuart Shapiro in 2013 and is headquartered in Weil am Rhein, Germany.

iSTAR Medical SA develops innovative ophthalmic implants. Its products include MINIject, STARflo and STAR Material. The company was founded by Michel Alvarez in 2011 and is headquartered in Wavre, Belgium.

Enterprise Therapeutics Ltd. operates as a drug discovery company that engages in the research and development of therapies for the treatment of respiratory diseases. It focuses on developing therapies for chronic obstructive pulmonary diseases, cystic fibrosis, and asthma. The company was founded by John Mervyn David Store in May 2014 and is headquartered in Falmer, the United Kingdom.

Imcheck Therapeutics SAS operates as a biopharmaceutical company which develops immunotherapeutic anti-cancer strategies for research. The company was founded by Olive Daniel in 2015 and is headquartered in Marseille, France.

Adorx Therapeutics Ltd. provides biotechnology, health care and therapeutics services. The company is headquartered in Edinburgh, the United Kingdom.

TOLREMO therapeutics AG engages in discovering and developing therapies for treating cancer patients. The firm serves on academic research laboratories, flourishing life sciences spin-offs and cutting-edge technology platforms. The company was founded by Stefanie Flückiger-Mangual, Wilhelm Krek, Karl-Heinz Altmann, Isaac Kobrin, and Emmanuel Savioz in March 2017 and is headquartered in Zurich, Switzerland.

Epsilogen Ltd. engages in the development of immunoglobulin E (IgE) antibodies to treat cancer. The firm offers IGEG platform technology based on combining the power of IgE and Immunoglobulin G (IgG) antibody molecules. The company was founded by Sophia Karagiannis and James Spicer and is headquartered in London, United Kingdom.

Curve Therapeutics Ltd. operates as a drug-discovery company. It engages on the development of innovative technologies to address undruggable disease-modifying targets, with an in-house focus on cancer. The company was founded in 2019 and is headquartered in London, the United Kingdom.

Lunac Therapeutics Ltd. engages in the identification and development of anticoagulants. The company was founded by Helen Philippou and Richard Foster on April 18, 2018 and is headquartered in Leeds, the United Kingdom.

Leucid Bio Ltd. is a clinical-stage biotechnology company based in London, UK. The British company develops novel, lateral car cell therapies for the treatment of refractory cancers, with a focus on developing next-generation cell therapies for the benefit of individuals with hard-to-treat solid tumors. The company's operations are based at Guys Hospital, enabling them to maintain a patient-centric focus. Leucid's goal is to develop CAR-T therapies with more durable responses, improving treatment outcomes and saving the lives of patients with refractory cancers. Leucid was established to translate 20 years of Kings College research in the CAR-T field and is led by a highly experienced management team, including scientific founder John Maher. Filippo Joseph Petti has been the CEO of the company since 2023.

Kinaset Therapeutics, Inc. engages in the provision of pharmaceutical services. It develops therapeutics for intractable diseases including severe asthma. The company was founded by Robert Clarke, Roger Heerman, and Frazer Morgan and is headquartered in Medfield, MA.

Epidarex Exeed Ltd. is a British biotechnology company that specializes in research and experimental development. The company is based in Edinburgh, UK. The company was founded in 2019 by Elizabeth Ann Roper and Henning Steinhagen, with Henning Steinhagen serving as the CEO since its inception.

Clyde Biosciences Ltd. provides developmental drug testing services. It offers drug screening, toxicity data analysis, direct measurements, and drug induced changes investigation services. Its services include calcium, voltage, contractility, in silico modeling, CiPA studies and bespoke R&D. The company was founded by Margaret Anne Craig, Godfrey Smith, Francis Burton, and Jon Cooper on March 9, 2012 and is headquartered in Glasgow, the United Kingdom.